Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Phase 1/2 Recruiting
55 enrolled
TARLATEM
Phase 1/2 Recruiting
70 enrolled
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Phase 1/2 Recruiting
196 enrolled
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Phase 1/2 Recruiting
83 enrolled
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Phase 1/2 Recruiting
52 enrolled
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Phase 1/2 Recruiting
139 enrolled
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
66 enrolled
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Phase 1/2 Recruiting
85 enrolled
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/2 Recruiting
45 enrolled
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phase 1/2 Recruiting
90 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Phase 1/2 Recruiting
204 enrolled
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Phase 1/2 Recruiting
152 enrolled
A Study of Mirdametinib in People With Central Nervous System Tumors
Phase 1/2 Recruiting
26 enrolled
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/2 Recruiting
62 enrolled
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
53 enrolled
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Phase 1/2 Recruiting
58 enrolled
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/2 Recruiting
23 enrolled
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 1/2 Recruiting
100 enrolled
TranspoCART19
Phase 1/2 Recruiting
27 enrolled
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2 Recruiting
141 enrolled
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2 Recruiting
30 enrolled
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1/2 Recruiting
31 enrolled
UHKT-PTC-TMI-1
Phase 1/2 Recruiting
16 enrolled
ADAPT-BLADDER
Phase 1/2 Recruiting
55 enrolled
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/2 Recruiting
20 enrolled
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Phase 1/2 Recruiting
37 enrolled
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/2 Recruiting
58 enrolled
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Phase 1/2 Recruiting
99 enrolled
PEEL-224
Phase 1/2 Recruiting
59 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
ASpiRE
Phase 1/2 Recruiting
78 enrolled
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
40 enrolled
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/2 Recruiting
49 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Phase 1/2 Recruiting
43 enrolled
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
40 enrolled
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Phase 1/2 Recruiting
20 enrolled
LUPARPED
Phase 1/2 Recruiting
25 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/2 Recruiting
42 enrolled
UPLIFT
Phase 1/2 Recruiting
30 enrolled
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Phase 1/2 Recruiting
65 enrolled
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Phase 1/2 Recruiting
40 enrolled
Mirda
Phase 1/2 Recruiting
24 enrolled
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Phase 1/2 Recruiting
8 enrolled
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/2 Recruiting
289 enrolled